Invesaro

Stocks Comparison

Enovis vs STERIS: revenue, profit, margins and growth compared

Enovis brought in $2.2B of revenue in fiscal 2025, STERIS $5.9B in fiscal 2026. Revenue changed by +6.7% at Enovis and +8.7% at STERIS on the year before, so STERIS grew faster. Enovis kept -52.7% of its revenue as net profit, STERIS 13.2%. Free cash flow was $19.9M at Enovis and $972.4M at STERIS.

Side by side, latest fiscal year

ENOVSTE
Fiscal year endedFY2025 (December 31, 2025)FY2026 (March 31, 2026)
Revenue$2.2B$5.9B
Revenue growth+6.7%+8.7%
Net income-$1.2B$782.3M
Net margin-52.7%13.2%
Free cash flow$19.9M$972.4M
Free cash flow margin0.9%16.4%
Earnings per share (diluted)-$20.75$7.93
Cash$36.4M$439.6M
Debt$1.3B$1.8B
Price to earningsn/a26.4
Market value$1.1B$20.4B
Dividend yieldn/a1.18%
Rank by revenue in sector#102 of 523 · Health care#55 of 523 · Health care

Over the years

Revenue
ENOV FY2018: $3.7BENOV FY2019: $3.3BENOV FY2020: $1.1BENOV FY2021: $1.4BENOV FY2022: $1.6BENOV FY2023: $1.7BENOV FY2024: $2.1BENOV FY2025: $2.2BSTE FY2019: $2.8BSTE FY2020: $3BSTE FY2021: $3.1BSTE FY2022: $4.2BSTE FY2023: $4.5BSTE FY2024: $5.1BSTE FY2025: $5.5BSTE FY2026: $5.9BFY18FY19FY20FY21FY22FY23FY24FY25FY26
ENOV $2.2BSTE $5.9B
Net income
ENOV FY2018: $140.2MENOV FY2019: -$527.6MENOV FY2020: $42.6MENOV FY2021: $71.7MENOV FY2022: -$13.3MENOV FY2023: -$33.3MENOV FY2024: -$825.5MENOV FY2025: -$1.2BSTE FY2019: $303.7MSTE FY2020: $407.7MSTE FY2021: $397.4MSTE FY2022: $243.9MSTE FY2023: $107MSTE FY2024: $378.2MSTE FY2025: $614.6MSTE FY2026: $782.3MFY18FY19FY20FY21FY22FY23FY24FY25FY26
ENOV -$1.2BSTE $782.3M
Net margin
ENOV FY2018: 3.8%ENOV FY2019: -15.9%ENOV FY2020: 3.8%ENOV FY2021: 5.0%ENOV FY2022: -0.9%ENOV FY2023: -1.9%ENOV FY2024: -39.2%ENOV FY2025: -52.7%STE FY2019: 10.9%STE FY2020: 13.5%STE FY2021: 12.8%STE FY2022: 5.8%STE FY2023: 2.4%STE FY2024: 7.4%STE FY2025: 11.3%STE FY2026: 13.2%FY18FY19FY20FY21FY22FY23FY24FY25FY26
ENOV -52.7%STE 13.2%
Revenue growth
ENOV FY2019: -9.3%ENOV FY2020: -66.3%ENOV FY2021: +27.3%ENOV FY2022: +9.6%ENOV FY2023: +9.2%ENOV FY2024: +23.5%ENOV FY2025: +6.7%STE FY2020: +8.9%STE FY2021: +2.5%STE FY2022: +35.9%STE FY2023: +7.4%STE FY2024: +13.3%STE FY2025: +6.2%STE FY2026: +8.7%FY19FY20FY21FY22FY23FY24FY25FY26
ENOV +6.7%STE +8.7%
Free cash flow
ENOV FY2018: $156.7MENOV FY2019: $5.5MENOV FY2020: $187.2MENOV FY2021: $251.9MENOV FY2022: -$161.3MENOV FY2023: $12.8MENOV FY2024: -$67.2MENOV FY2025: $19.9MSTE FY2019: $349.8MSTE FY2020: $376MSTE FY2021: $450.4MSTE FY2022: $397.2MSTE FY2023: $395MSTE FY2024: $613MSTE FY2025: $778MSTE FY2026: $972.4MFY18FY19FY20FY21FY22FY23FY24FY25FY26
ENOV $19.9MSTE $972.4M

Fiscal years as each company reports them; the two may end in different months.

Questions about Enovis and STERIS

Which is bigger by revenue, Enovis or STERIS?

STERIS is bigger by revenue: $5.9B in fiscal 2026, against $2.2B for Enovis in fiscal 2025.

Which keeps more of its revenue as profit, Enovis or STERIS?

Enovis had a net margin of -52.7% in fiscal 2025; STERIS had 13.2% in fiscal 2026.

Which grew revenue faster, Enovis or STERIS?

In their latest fiscal years revenue changed by +6.7% at Enovis and +8.7% at STERIS.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies